NCT07785024
CEST for Prostate Biopsy
StatusNot Yet Recruiting
PhaseNot applicable
Primary completion (estimated)
At risk: Primary completion moved at least 2 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Start date: Sep 2026 to Dec 2026 Show 5 more changesShow less
- Eligibility criteria expanded, about 5 words
- Primary and study completion pushed from Sep 2027 to Dec 2027
- Secondary endpoints: details revised at 1 of 1 entry
- Site details revised
- Study description expanded, about 2 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Aiding the detection of prostate cancer
Timeframe: 1 year
Secondary (1)
Aiding risk stratification and the decision whether targeted prostate biopsy is justified
Arms and interventions
Diagnostic Test: Saturation Transfer (ST)-MRIExperimental
Non-contrast magnetic resonance imaging "Saturation Transfer" scans consisting of magnetization transfer (MT) and chemical exchange saturation transfer (CEST)
Procedures: Biopsy-Guided Therapy Selection
Sites
1 site in 1 country
- Sunnybrook Health Sciences CentreToronto, Ontario, Canada